Stratatech Corporation


BiotechProfiles™ is the premier resource for jobs, company information, professional networking and productivity tools in the Madison, Wisconsin biotechnology and medical device industry. Recognized as one of the premier emerging biotechnology clusters in the U.S., this robust industry sector comprises nearly 10,000 employees in approximately 150 companies. BiotechProfiles also maintains a unique directory of the largest 250 pharmaceutical companies worldwide, including business development contacts whenever available. This tool is indispensable for executives pursuing strategic alliances and technology licenses.
Designed as a suite of easy to use, searchable databases that are continually updated, BiotechProfiles serves the needs of biotech business development and operational executives in early stage companies, as well as the general public. With these tools you can quickly bypass the data collection and screening stage and immediately focus on solving your strategic partnering or operational needs. We've assembled your background data for you!
  Next »

BiotechProfiles is also the premier site for data on Biotechnology Companies in Madison Wisconsin, Biotechnology Jobs in Madison Wisconsin

Biotechnology Companies in Madison Wisconsin; Biotechnology Jobs in Madison Wisconsin
  « Previous | Next »

Biotechnology Business Development, Partnering and Strategic Alliances

Biotechnology Business Development, Partnering and Strategic Alliances
  « Previous | Next »

Madison Biotechnology Companies; Madison Biotechnology Jobs

Madison Biotechnology Companies; Madison Biotechnology Jobs
  « Previous | Next »

List or rank of Largest Pharmaceutical Companies Worldwide

List of rank of Largest Pharmaceutical Companies Worldwide
  « Previous


Company Profile

Stratatech Corporation, a unit of Mallinkcrodt Pharmaceuticals, is a regenerative medicine company focused on skin regeneration therapies. These products are made using the company’s proprietary NIKS® cells – a consistent and well-characterized source of human keratinocyte progenitor cells that faithfully reproduces normal epidermal skin architecture and barrier function. The company is using these progenitor cells to create a portfolio of therapeutic tissues to treat orphan and ultra-orphan indications such as severe burns and other complex skin defects, as well as large and growing indications such as non-healing ulcers. The company’s flagship product, StrataGraft® tissue, is in Phase III clinical development for the treatment of severe burns. The company’s second therapeutic product, ExpressGraft™ anti-infective tissue, has recently received FDA approval to enter clinical testing as a treatment for non-healing diabetic foot ulcers.
Business Sectors
Pharmaceuticals Human Diagnostics  
Med or Lab Devices   Lab Reagents or Services
Drug Manufacturing   Food & Agribusiness  
CRO   Bioinformatics or Software  
Company History
Stratatech was founded in 2000. In 2017, the company was acquired by Mallinckrodt Pharmaceuticals for up to $200 million. The company continues to operate its clinical development and manufacturing operations in Madison.
Stratatech Corporation
Address 505 South Rosa Road, Suite 169
[Map] Madison
Phone 608-441-2750
Fax 608-441-2757
Website Link
Head B. Lynn Allen-Hoffman, PhD
Company Statistics
Global Headcount 70
Local Headcount 70
Year Founded 2000
Ownership Subsidiary
Stock Exchange

Parent Company
Divisional Level Mallinckrodt Pharmaceuticals
Senior Level Mallinckrodt PLC
Global Headcount
Stock Exchange
Reference Documents
Corporate Profile
2015 - Stratatech Corporate Profile [View]
2018 - Stratatech Expands Clinical Trials into Pediatric Patients [View]
2017 - Stratatech Sale Price was up to $200 million [View]
2015 - Stratatech Awarded $247M BARDA Contract [View]
2013 - Impressive Clinical Results of StrataGraft skin tissue [View]
2009 - Stratatech's Skin Substitute Fights Infection [View]
2008 - StrataGraft Phase I Trial a Success [View]
2007 - Growing Skin; Stratatech Corp Profiled [View]
2000 - Stratatech Profiled [View]
Selected Press Releases
2016 - Mallinckrodt to Acquire Stratatech [View]
2015 - Stratatech Awarded $247M BARDA Contract [View]
2015 - Positive POC Clinical Trial Results [View]
2013 - Stratatech Awarded $47M BARDA Contract [View]
2013 - Stratatech Announces Impressive Clinical Results for StrataGraft [View]
2012 - Positive Interim Results of StrataGraft Clinical Trial [View]